pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
BOEHRINGER INGELHEIM · news · pharmadog
← back to BOEHRINGER INGELHEIM
News mentioning BOEHRINGER INGELHEIM
28
stories
19h
Boehringer places phase 1 study of investigational drug on hold to examine ‘safety event’
fiercebiotech
1d
Why pediatric rare oncology outperforms in a volatile biotech market
biospace
2d
Leo Pharma buys rare skin disease drug in $435M deal
biopharma dive
2d
LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drug
biospace
4d
Leo ‘really strengthening’ pipeline with $435M deal for Tanabe rare skin disease drug awaiting FDA nod
fiercebiotech
4d
Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague
fiercebiotech
8d
Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision
fiercebiotech
9d
After billions in deals, Insilico CEO promises: ‘You haven't seen anything yet’
biospace
15d
A COPD drug from China draws $115M in venture funding
biopharma dive
21d
Chutes & Ladders—Legend CEO departs without successor in place
fiercebiotech
23d
‘Reverse mergers are increasingly popular’: Caldera hops on Synlogic’s Nasdaq listing
fiercebiotech
Jul 21, 26
Indian generics maker Lupin seeds US spinout Kaveri with cash, clinical-phase cancer assets
fiercebiotech
Jul 17, 26
How well are AI-discovered drugs faring in the clinic?
biopharma dive
Jul 8, 26
Novartis cuts New Jersey jobs; OTR, LG Chem explore China cancer drugs
endpoints
Jul 2, 26
A PureTech startup banks $180M for a new IPF drug
biopharma dive
Jun 11, 26
STAT+: An obesity drug deep-dive, and peptides move mainstream
stat
Jun 8, 26
Major readouts from the annual diabetes conference
stat
Jun 7, 26
#ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effects
endpoints
Jun 7, 26
STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
stat
Jun 4, 26
Lilly, Boehringer retrench in Germany on proposed health spending cuts
endpoints
Jun 4, 26
STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and more
stat
May 19, 26
STAT+: Pharmalittle: We’re reading about a Supreme Court setback for pharma, TrumpRx expands and much more
stat
May 18, 26
STAT+: Supreme Court rejects challenge to Medicare drug price negotiation
stat
May 1, 26
Boehringer appoints pharma veteran for corporate affairs post; BlueRock CSO heads for the exit
endpoints
Apr 30, 26
Avalyn, in pursuit of better lung drugs, banks $300M in an IPO
biopharma dive
Apr 28, 26
Boehringer dual-acting obesity shot hits mark in Phase 3 trial
biopharma dive
Apr 28, 26
STAT+: Pharmalittle: We’re reading about warnings over Trump’s MFN plan, Purdue Pharma sentencing, and more
stat
Apr 28, 26
Boehringer, Zealand’s obesity shot looks as good as Novo's Wegovy, but weaker than Lilly's Zepbound
endpoints
